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Epidemiologic evidence associating obesity and cancer accumulated over 
last two decades pointing to potentially preventable forms of cancer disease. 
Observational prospective analyses point to breast and colon cancer as most 
influenced by obesity-linked lifestyle habits. Other tumor-types can comprise 
to this group as well (endometrium, esophagus, liver, stomach, thyroid, pan-
creas, and prostate cancer), according to epidemiological data, but with lesser 
level of certainty. Randomized studies of lifestyle interventions are still scarce 
in this area of research, despite being urgently needed. Different pathophysi-
ological mechanisms for obesity-cancer link are proposed in literature.  Endo-
crine factors, deregulated signaling cascades, oxidative stress, and chronic 
inflammation are implicated as obesity-related carcinogenic processes. Con-
sidering growing prevalence of obesity, expert recommendations for lifestyle 
change (healthy nutrition, physical activity) are widely suggested as a main 
strategy in primary and secondary prevention of adiposity-related cancers.
 
IntroductIon
Body fat accumulation represents evolutionary advantage for sur-vival in natural habitat due to its many physiologic roles (energy 
storage, thermoregulation, endocrine regulation etc.). On the other side, 
pathophysiological effect of excess body fat (especially abdominal, vis-
ceral fat) on overall risk of death and cardiovascular mortality in par-
ticular, is well elaborated in literature. Increasing body of scientific evi-
dence corroborates additional etiopathogenetic roles of adiposity in 
carcinogenesis and mortality from malignant diseases in general and 
from death of cancers of various specific organs.
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Overview
Table 1
Body fat composition description with Body Mass Index 
(BMI) according to Word Health Organization (WHO) criteria.
Body Mass Index (kg/m2)
Underweight Below 18,5
Overweight 25 to 30
Obese 30 and more
BMI is calculated by dividing body mass in kilograms by the square of height in meters. 
This is the most frequently used variable for body fat composition description. It is considered 
a crude but reliable measure. Abdominal or visceral fat (most pathophysiologicaly active part 
of fat-tissue compartment) is sometimes better described with waist circumference. Accurate 
measurement of visceral fat is performed with computed tomography.
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obesity increases general cancer-
death risk
Epidemiologic data on obesity association with cancer 
had accumulated and gradually matured over a period of 
more than two decades, arising from smaller, heteroge-
neous and largely retrospective studies to larger-sampled, 
focused and more often prospective observational trials, 
with elaborated multivariate statistical backup. Calle EE 
and coworkers (1) summarized data from prospective co-
hort that included nearly 60000 cancer-death cases dur-
ing 16 years of follow-up. Association of obesity and death 
from breast, uterus, and ovary cancer was found in wom-
en, and from stomach and prostate cancer in men. Both 
sexes’ cancer-deaths in obese individuals were more fre-
quent for esophagus, colon, liver, gallbladder, pancreas 
and kidney cancer-cases. The quantum of scientific infor-
mation regarding association of body fat with malignan-
cy grew sufficiently in following years to reach higher 
levels of evidence (as much as can be expected from epi-
demiologic data), especially in case of breast and colon 
cancer. To date there are several epidemiological reports 
that summarize different aspects on obesity–cancer as-
sociation. A comprehensive report was issued in 2007 by 
panel of experts  (2) finding a clear connection between 
obesity and breast, colon, endometrial, esophageal, kid-
ney and pancreatic cancer. Probable association was pre-
sumed for prostate and gallbladder cancer. Published risk 
variables for each cancer-site tested vary considerably be-
tween studies, depending on population under research, 
applied anthropometric measures and their timing, to-
bacco consumption, sex, as well as other possible covari-
ates (3). Most elaborated explorations are available for 
breast and colon cancer, providing epidemiologic evi-
dence for association with obesity that is considered con-
vincing (breast and colon cancers are among most fre-
quent cancers so the numbers of analyzed patients are 
greatest – a total of several hundred thousands of patients 
are included in the meta-analyses up to now).
obesity and breast cancer
Among corner-stone studies for breast cancer (BC) are 
results from van der Brandt (4) concluding from prospec-
tive data that overweight postmenopausal women are at 
significantly higher risk for BC development – relative risk 
(RR) was 1.43 for 27–29 vs. <21 kg/m2 BMI-group. 
Moreover, recent meta-analysis from Chan DS (5); 
(N≈500000) showed a significant association between 
adiposity and risk of death from BC after surgery and 
oncologic therapy (RR 1.34 and 1.7 in BMI-cohorts 
25–30 or 35–40 kg/m2 versus patients with normal body 
mass index). The influence of excess BMI and increased 
risk of death from BC appears to be linear (RR increase 
of 0.14 for each 5 kg/m2 BMI). In other words, obese 
women (according to BMI) despite complete oncological 
treatment have larger risk of death from recurrence/dis-
semination for at least 25% (range 25–68%) than patients 
with normal BMI. Association between body-fat and BC 
appears to extend for both pre- and postmenopausal dis-
ease (6). The link between adiposity and worse BC prog-
nosis can partly be explained with higher incidence of 
unfavorable disease-stage (lymph node involvement, 
higher grade, larger tumors, and more hormone-receptor 
negative disease) that is more often seen in obese women 
in some studies (7). On the other hand multivariate analy-
sis confirmed obesity as independent prognostic factor, 
after correction for worse disease stage. It is still a matter 
of debate whether phenomenon applies in the same way 
(or even exists) also for estrogen receptor (ER) negative 
disease (about 20 to 30% of all breast cancer patients). 
Described data on postmenopausal women appear to ap-
ply to male breast cancer patients but with much less cer-
tainty due to very small number of patients and consecu-
tive paucity of reliable study data (8). 
obesity and colon cancer
Colon cancer also develops more frequently among 
obese individuals (9) (risk-increase varies from 14 to 41% 
depending on fat burden measured as BMI). Population 
of treated obese colon cancer patients also appear to be at 
higher risk of colon cancer-related death than survivors 
with normal BMI (10) (RR 1.35 for BMI cohort >30 kg/



















Epidemiologic association between risk of cancer and obesity vary a lot 
for majority of cancers among different studies. Level of evidence is consid-
ered as ‘convincing’ only for breast and colon cancer, due to vast amount 
of accumulated prospective data.  List provided here should not be consid-
ered as definitive due to large number of ongoing studies in this area of 
research. Data in table are summarized from references 1–5.
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nomena do not apply or at least applies to a lesser extent 
to rectal cancer (11). Furthermore, there is a difference in 
the effect on right- and left-sided (distal) colon cancer, 
with stronger association of the former (colon descendens 
or left part of transversum) with obesity-induced carcino-
genesis (12). There is still no plausible explanation for 
these differences. 
Alternative possibilities for explanation of described 
obesity-cancer mortality association include suboptimal 
the rapy (under-dosing, complicated course of treatment, 
less -effective regimens) (13), and the possibility of 
enhanc ed tumor resistance to therapy due to the adipos-
ity (14).
Hypothesized mechanisms of action
Reports on exact mechanisms of obesity and tumori-
genesis association are still highly speculative and equi-
vocal despite emanating from area of extensive research. 
Bioactive factors derived from adipose tissue or under its 
influence could change (pre)malignant target cells or tis-
sue affecting their proliferation or differentiation- poten-
tial, survival, metabolism or migration thus triggering 
or promoting chain of events that could lead to neopla-
sia (15). 
Endocrine factors are among must studied putatively 
tumorigenic molecules directly associated with obesity. 
These include estrogen, insulin, insulin-like growth factor 
– 1 (IGF-1), leptin, decreased adiponectin. Mainly the 
anabolic i.e. growth-stimulatory effects in direct or indi-
rect manner are hypothesized to promote tumorigenesis 
by these mediators (16). Leptin is also supposed to exert 
indirect proangiogenic function as well, by activation of 
vascular endothelial growth factor (VEGF) (17). 
Disturbed endocrine milieu can even go beyond obe-
sity, concerning carcinogenesis, as recent confirmatory 
data point out that metabolic syndrome (fasting blood 
glucose level, high blood pressure, hypertriglyceridemia) 
are independent risk factors for endometrial cancer devel-
opment even after correction for obesity in multivariate 
analysis (10, 18). 
Besides extracellular signals, subsequent intracellular 
signal transduction, can become disarranged and contrib-
ute to pro-neoplastic events in connection with obesity. 
For example mTOR signaling pathway and the AMP-
kinase system may in the context of adiposity lead to dis-
turbance of the cell cycle and cancer-promotion (19). 
There is also indirect evidence of impaired immune 
response (20), deregulation of oxidative stress (21) and 
stimulation of chronic pro-inflammatory stimulation by 
factors secreted from immune and inflammatory cells 
infiltrating adipose tissue (for instance cytokines like IL-
6, TNF-a) with carcinogenic potential (22). 
need for interventional research of 
“adiponcosis”
Aggregate result of observational studies should pave 
the way for intervention studies that further analyze 
proven statistical association of cancer with obesity. Un-
fortunately, comprehensive cancer incidence estimation 
in prospective, randomised setting would claim for very 
long follow-up and large number of participants in order 
to detect significant effect, so interventional studies to 
date are usually based on indirect biomarkers of poten-
tial tumorigenesis (like precancerous lesions) (11, 23). 
Only indirect preliminary data of small studies and 
meta-analyses point to a more favorable course after the 
reduction of body weight or adoption of positive life-
style-change (24). For example, methods of bariatric 
surgery (stomach banding, insertion of a balloon, intes-
tinal bypass etc.) appear to be associated with lowering 
the risk of colorectal cancer (25). In addition, lifestyle-
changing interventions able to produce sustainable low-
ering of BMI, could not easily be tested for anti-carci-
nogenic potential in prospective, randomized setting 
(26, 27). Considering vastness of published epidemio-
logical data some authors propose neologism “adiponco-
sis” for etiopathogenetic conundrum found between 
obesity and cancer (28).
conclusIons
According to the described body of evidence guidelines 
for changing the lifestyle of obese patients are promoted 
by different expert societies (American Cancer Society 
(29), National Comprehensive Cancer Network (30)). 
Patients treated especially for breast and colon cancer 
should thrive to reduce excess body fat, or at least keep 
present body weight after oncological therapy of localized 
cancer. Methods to achieve such a goal should include 
multimodal approach and be based on motivational sup-
port and follow-up (healthy diet, regular physical activity, 
support by regular personal, written or telephone consul-
tation) (24, 25, 31).
Given the increasing incidence and prevalence of ex-
cessive body mass index in the population of Western 
civilization (32), the motivation for positive change in 
lifestyle of healthy and already diagnosed persons, should 
become a priority task for physicians as well as other pro-
fessionals in biomedical field.
A reasonable assumption is that the reduction of over-
weight by effective lifestyle adaptation will significantly 
improve primary and secondary prevention of cancer 
diseases, quantitatively comparable with the overall re-
sults of the current curative oncological methods (33, 
34).
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